| 中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
|---|---|---|---|---|
| （d（CH2）51，Tyr（Me）2，Arg8）-血管加压素 | Vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O-methyl-L-tyrosine)-8-L-arginine- | 73168-24-8 | C52H74N14O12S2 |
|
| voreloxin中间体 | ethyl 1,4-dihydro-7-[(S,S)-3-methoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylate | 685880-17-5 | C20H23N5O4S |
|
| voreloxin中间体 | ethyl 7-chloro-1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylate | 174726-87-5 | C14H10ClN3O3S |
|
| v-三唑并[4,5-d]嘧啶,(3H),3-环戊基-7-偏基硫代- | 3-cyclopentyl-7-methylsulfanyl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine | 17050-87-2 | C10H13N5S |
|
| [[(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲氧基-羟基磷酰]2-丙基戊酸酯 | Valproyl-adenylic acid | 140233-88-1 | C18H28N5O8P |
|
| [3-(4-吗啉基)苯基]硼酸盐酸盐 | VX 702 | 745833-23-2 | C19H12F4N4O2 |
|
| [2-[(17-乙烯基-3-羟基-10,13-二甲基-2,3,4,5,6,7,8,9,11,12,14,15,16,17-十四氢-1H-环戊二烯并[a]菲-4-基)氧基]-5-羟基-4-甲氧基-6-甲基四氢吡喃-3-基]乙酸酯 | Verrucoside | 141544-59-4 | C30H48O7 |
|
| [1aR-(1aalpha,4beta,4abeta,7alpha,7abeta,7balpha)]-十氢-1,1,4,7-四甲基-1H-环丙并[e]薁-4-醇 | (+)-viridiflorol | 552-02-3 | C15H26O |
|
| [13C5，15N]-维格列汀标准品 | Vildagliptin-13C5,15N | 1044741-01-6 | C17H25N3O2 |
|
| [(3R)-3-(羟甲基)-1-哌啶基][4-[2-(4-甲氧基苯基)乙炔基]苯基]甲酮 | VU0463597 | 1382481-79-9 | C22H23NO3 |
|
| [(3-甲氧基-4-氧代-1-环己-2,5-二烯亚基)甲基氨基]硫脲 | vanillinthiosemicarbazone | 5351-92-8 | C9H11N3O2S |
|
| [(2R,3S,4R,5R)-4-羟基-2,5-二[[(E)-3-(4-羟基苯基)丙-2-烯酰基]氧基甲基]-2-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-[[(E)-3-(4-羟基-3-甲氧基苯基)丙-2-烯酰基]氧基甲基]四氢吡喃-2-基]氧基四氢呋喃-3-基](E)-3-(4-羟基苯基)丙-2-烯酸酯 | Vanicoside B | 155179-21-8 | C49H48O20 |
|
| [(2R,3S,4R,5R)-2-[(2R,3R,4S,5S,6R)-3-乙酰氧基-4,5-二羟基-6-[[(E)-3-(4-羟基-3-甲氧基苯基)丙-2-烯酰基]氧基甲基]四氢吡喃-2-基]氧基-4-羟基-2,5-二[[(E)-3-(4-羟基苯基)丙-2-烯酰基]氧基甲基]四氢呋喃-3-基](E)-3-(4-羟基苯基)丙-2-烯酸酯 | Vanicoside A | 155179-22-9 | C51H50O21 |
|
| [(13S)-3beta-羟基-7,15-海松二烯-19-基]beta-D-阿卓吡喃糖苷 | Virescenoside B | 28251-74-3 | C26H42O7 |
|
| [(13S)-2alpha,3beta-二羟基-7,15-海松二烯-19-基]beta-D-阿卓吡喃糖苷 | Virescenoside A | 28251-73-2 | C26H42O8 |
|
| Vicriviroc苹果酸盐;1-[(4,6-二甲基-5-嘧啶基)羰基]-4-[(3S)-4-[(1R)-2-甲氧基-1-[4-(三氟甲基)苯基]乙基]-3-甲基-1-哌嗪基]-4-甲基哌啶苹果酸盐 | 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methylpiperidine malate | 541503-81-5 | C32H44F3N5O7 |
|
| Verucerfont; 3-(4-甲氧基-2-甲基苯基)-2,5-二甲基-N-[(1S)-1-(3-甲基-1,2,4-恶二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺 | Verucerfont | 885220-61-1 | C22H26N6O2 |
|
| Verdinexor（KPT-335）抑制剂 | verdinexor | 1392136-43-4 | C18H12F6N6O |
|
| Val-Ala对硝基苯胺乙酸盐 | Val-Ala p-Nitroanilide acetate salt | 108321-94-4 | C16H24N4O6 |
|
| VX-661/VX6611-(2,2-二氟-1,3-苯并二氧戊环-5-基)-N-[1-[(2R)-2,3-二羟基丙基]-6-氟-2-(2-羟基-1,1-二甲基乙基)-1H-吲哚-5-基]-环丙烷甲酰胺 | (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | 1152311-62-0 | C26H27F3N2O6 |
|
| VUF11207三氟乙酸酯盐 | VUF11207 | 1378524-41-4 | C27H35FN2O4 |
|
| VU590二盐酸盐 | VU 590 dihydrochloride | 313505-85-0 | C24H34Cl2N4O7 |
|
| VU 0361737; N-(4-氯-3-甲氧基苯基)-2-吡啶甲酰胺 | VU0361737 | 1161205-04-4 | C13H11ClN2O2 |
|
| VTP-27999 盐酸盐 | VTP-27999 Hydrochloride | —— | C26H42Cl2N4O5 |
|
| VP/甲基丙烯酸二甲氨基乙酯共聚物 | 2-(Dimethylamino)ethyl 2-methylprop-2-enoate;1-ethenylpyrrolidin-2-one | 160984-81-6 | C14H24N2O3 |
|
| VP/二十碳烯共聚物 | 1-ethenylpyrrolidin-2-one;icos-1-ene | 28211-18-9 | C26H49NO |
|
| VP/VAc共聚物 | Pvp-VA | 25086-89-9 | C10H15NO3 |
|
| VE烟酸酯 | alpha-tocopherol nicotinate | 51898-34-1 | C35H53NO3 |
|
| VER155008抑制剂 | VER155008 | 1134156-31-2 | C25H23Cl2N7O4 |
|
| VELPATASVIR中间体 | (3S,5S)-1-(tert-butoxycarbonyl)-5-(methoxycarbonyl)pyrrolidine-3-carboxylic acid | 1378388-35-2 | C12H19NO6 |
|
| VELPATASVIR 中间体 | (2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carboxylic acid | 1335316-40-9 | C13H22N2O5 |
|
| VEL 0230 | VEL-0230 | 221144-20-3 | C14H24NO5*Na |
|
| VEGFR2激酶抑制剂IV | 3-(thien-3-yl)-6-(4-methoxyphenyl)-pyrazolo(1,5-A)pyrimidine | 216661-57-3 | C17H13N3OS |
|
| VEGFR2激酶抑制剂II | VEGF Receptor 2 Kinase Inhibitor II | 288144-20-7 | C17H15BrN2O |
|
| VECTOMER?4051乙烯醚 | Bis[[4-(ethenoxymethyl)cyclohexyl]methyl] Benzene-1,4-dicarboxylate | 209072-72-0 | C28H38O6 |
|
| V-9-M缩胆囊素九肽 | Valyl-prolyl-valyl-glutamyl-alanyl-valyl-aspartyl-prolyl-methionine | 99291-20-0 | C42H69N9O14S |
|
| :ZMMBI:抗氧剂ZMMBI | Vanox ZMTI | 61617-00-3 | C16H14N4S2Zn |
|
| (氯亚甲基)二甲基氯化铵 | Vilsmeier reagent | 3724-43-4 | C3H7ClN*Cl |
|
| (乙烯基二甲氧基硅烷基)-苯 | vinylphenyldimethoxysilane | 20151-57-9 | C10H14O2Si |
|
| (±)-鸭咀花碱 | vasicine | 6159-56-4 | C11H12N2O |
|
| (±)-驴食草酚 | Vestitol | 56701-24-7 | C16H16O4 |
|
| (~49~V)钒 | Vanadium-49 | 14392-01-9 | V |
|
| (p-Me)-苯基乙烯基亚砜 | vinyl-4-tolylsulfoxide | 36832-47-0 | C9H10OS |
|
| (Z,Z)-9,12-十烷二烯酸二聚体与乙二胺的共聚物 | Versamid 140 | 12624-35-0 | C38H72N2O4 |
|
| (S)-N-((5-(乙基磺酰基)吡啶-2-基)甲基)-7-异丙基-6-(((1R,4S)-4-(三氟甲基)环己基)甲基)-6,7-二氢-5H-吡咯并[3,4-B]吡啶-3-甲酰胺 | Vimirogant | 1802706-04-2 | C27H35F3N4O3S |
|
| (S)-2-((s)-2-氨基-3-甲基丁酰胺)丙酸 | Val-Ala | 27493-61-4 | C8H16N2O3 |
|
| (R,S)-布洛芬乙烯基酯 | vinyl 2-(4-isobutylphenyl)propanoate | 134018-89-6 | C15H20O2 |
|
| (R)-特拉匹韦 | VRT-127394 | 923270-50-2 | C36H53N7O6 |
|
| (OC-6-22)-三(4-羟基-3-亚硝基苯甲醛-N3,O4)-高铁酸钠 | Viridomycin A | 52970-22-6 | C21H12FeN3NaO9 |
|
| (E)-4-[2-[4-[(4E,6E,14E,16Z)-11-乙基-10,12-二羟基-3,17-二甲氧基-7,9,13,15-四甲基-18-氧代-1-氧杂环十八碳-4,6,14,16-四烯-2-基]-3-羟基戊烷-2-基]-2-羟基-5,6-二甲基四氢吡喃-4-基]氧基-4-氧代丁-2-烯酸 | Viranamycin A | 139595-03-2 | C41H64O13 |
|
联系我们
关注我们
公众号
